Minimal Invasive, Safe Treatment of the Neurogenic Bladder with Botulinum-A-Toxin in Children with Myelomeningocele;Minimalinvasive, sichere Behandlung der neurogenen Blase bei Myelomeningozelen-Kindern mit Botulinum-Toxin A

Aktuelle Urologie

Volumn 35, Issue 1, 2004, Pages 49-53

  Lusuardi, L ^a   Nader, A ^a   Koen, M ^a   Schrey, A ^a   Schindler, M ^a   Riccabona, M ^a  

^a Krankhs der Barmherzigen Schwestern ^*  (Austria)

Author keywords

Bladder; Botulinum A toxin; Children; Myelomeningocele

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; BLADDER CAPACITY; CHILD; CLINICAL ARTICLE; DETRUSOR MUSCLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERREFLEXIA; INCONTINENCE; INTERMITTENT CATHETERIZATION; KIDNEY SCINTISCANNING; MALE; MENINGOMYELOCELE; MICTURITION REFLEX; NEUROGENIC BLADDER; PRESSURE; URODYNAMICS;

EID: 1642299695     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-812520     Document Type: Article

References (30)

1. Bauer SB, Hallett M, Khoshbin S, Lebowitz RL, Winston KR, Gibson S, Colodny AH, Retik AB. Predictive value of urodynamic evaluation in newborns with myelodysplasia. Jama 1984; 3, 252: 650-652
2. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981; 126: 205-209
3. McGuire EJ, Fitzpatrick CC, Wan J, Bloom D, Sanvordenker J, Ritchey M, Gormley EA. Clinical assessment of urethral sphincter function. J Urol 1993; 150: 1452-1454
4. Hernandez RD, Hurwitz RS, Foote JE et al. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 1994; 152: 1582-1585
5. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-697
6. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology, 2002; 59: 325-327 discussion,: 327-328
7. Bump RC, Elser DM, Theofrastous JP, McClish DK. Valsalva leak point pressures in women with genuine stress incontinence: reproducibility, effect of catheter caliber, and correlations with other measures of urethral resistance. Continence Program for Women Research Group. Am J Obstet Gynecol 1995; 173: 551-557
8. Bates P, Bradley WE, Glen E, Griffiths D, Melchior H, Rowan D, Sterling A, Zinner N, Hald T. The standardization of terminology of lower urinary tract function. J Urol 1979; 121: 551-554
9. O'Donnell B, Puri P. Treatment of vesicoureteric reflux by endoscopic injection of Teflon. Br Med J (Clin Res Ed) 1984; 289: 7
10. Stenberg A, Lackgren GA. New bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. J Urol, part 2 1995; 154: 800
11. Coffield JA, Considine RV, Simpson LL The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett (ed.). Therapy with botulinum toxin. New York: Marcel Dekker Inc, 1994
12. Drachman DB. Botulinum toxin as a tool for research on the nervous system. In: Simpson LL (ed.). Neuropoisons: Their Pathophysiological Actions. New York: Plenum Press, 1971; 115: 325-347
13. Fex S, Sonesson B, Thesleff S et al. Nerve implants in botulinum poisoned mammalian muscle. J Physiol (Lond) 1966; 184: 872
14. Kikkawa DO, Cruz Jr RC, Christian WK, Rikkers S, Weinreb RN, Levi L, Granet DB. Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 2003; 135: 427-431
15. Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch Phys Med Rehabil 2003; 84: 444-454
16. rd J. Botulinum toxin A: a review of 1085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003; 61: 317-324
17. Rollnik JD, Meier PN, Manns MP, Goke M. Antral injections of botulinum a toxin for the treatment of obesity. Ann Intern Med 2003; 18,138: 359-360
18. Glogau RG. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin J Pain 2002; 18: S191-S197
19. O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002; 18: S182-S190
20. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1989; 139: 919-922
21. Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F. Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol 2001; 248 1: 28-30
22. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-396
23. rd JF, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299-303
24. Coffield JA, Considine RV, Simpson LL Clostridial neurotoxins in the age of molecular medicine. Trends Microbiol, 1994; 2: 67-69 discussion,: 69-72
25. Mellanby J. Comparative activities of tetanus and botulinum toxins. Neuroscience 1984; 11: 29-34
26. Paiva A de, Poulain B, Lawrence GW, Shone CC, Tauc L, Dolly JO. A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem 1993; 5, 268: 20838-20844
27. Simons DG, Travell JG. Myofascial origins of low back pain. 3. Pelvic and lower extremity muscles. Postgrad Med 1983; 73: 99-105, 108
28. Huber A. Use of botulinum toxin in ophthalmology. Ther Umsch 1990; 47: 320-328
29. Cayan S, Coskun B, Bozlu M, Acar D, Akbay E, Ulusoy E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res 2003; 30: 399-404
30. Park JM, Bauer SB, Freeman MR, Peters CA. Oxybutynin chloride inhibits proliferation and suppresses gene expression in bladder smooth muscle cells. J Urol 1999; 162: 1110-1114